NYSE
28.81USD
+1.30 (+4.73%)
We have scored 90 news catalysts on Hims & Hers Health, Inc. (HIMS) over the past 12 months. The biggest single-day move next to one of them came Feb 9, 2026, when HIMS closed −16.0%: “Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War”. Coverage across the window leans negative (average ticker sentiment −0.19). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.4B
P/E
—
EPS
—
Beta
2.41
52W range
13.74-65.299
Day range
27.14–29.44
Open
27.38
Prev close
27.51
Volume
11.9M
Avg volume
16.7M
Dividend
0.00
IPO
2019-09-13
Analysts publish price targets on HIMS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
11 analyst price targets from $23 to $42
as of 2026-09-13
The market is 14% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Hims & Hers Health, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Hims & Hers Health, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for HIMS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
The reconstruction
The price sits 14% below the median published target and at the 36th percentile by count, meaning the market leans bearish and has largely refused the bull case while absorbing the immediate shock of recent regulatory actions.
What the disagreement turns on
Does the FTC lawsuit and regulatory scrutiny permanently impair Hims' ability to convert its 73.8% gross margins into meaningful free cash flow, or is the current 3.2% FCF margin a temporary distortion that resolves as the company scales? The available data can measure consumer attention and unit volumes to see if the regulatory headlines are actually deterring users, but it cannot directly measure the legal outcomes or pricing power.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
